NAV

Istaroxime

Targets (2)
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Istaroxime
Accession Number
DB06157
Description
Not Available
Type
Small Molecule
Groups
Investigational
Structure
Thumb
3D
Similar Structures
Weight
Average: 360.498
Monoisotopic: 360.241292898
Chemical Formula
C21H32N2O3
Synonyms
  • 3-((2-Aminoethoxy)imino)-5alpha-androstan-6,17-dione
  • Istaroxime
External IDs
  • PST 2744
  • PST-2744
  • ST-2744

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

Investigated for use/treatment in heart disease.

Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action

Reduces the sodium-potassium adenosine triphosphatase (ATPase) activity and stimulates the sarcoplasmic calcium ATPase isoform 2 reuptake function.

TargetActionsOrganism
USarcoplasmic/endoplasmic reticulum calcium ATPase 2Not AvailableHumans
USodium/potassium-transporting ATPase subunit alpha-1Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Istaroxime hydrochlorideR9SOU1JG5F374559-48-5AXHJYJDJXNOGNI-ROJIRLEOSA-N

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
W40687GO3S
CAS number
203737-93-3
InChI Key
MPYLDWFDPHRTEG-PAAYLBSLSA-N
InChI
InChI=1S/C21H32N2O3/c1-20-7-5-13(23-26-10-9-22)11-17(20)18(24)12-14-15-3-4-19(25)21(15,2)8-6-16(14)20/h14-17H,3-12,22H2,1-2H3/b23-13+/t14-,15-,16-,17+,20+,21-/m0/s1
IUPAC Name
(3aS,3bR,5aS,7E,9aR,9bS,11aS)-7-[(2-aminoethoxy)imino]-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthrene-1,5-dione
SMILES
C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O

References

General References
Not Available
ChemSpider
8017549
ChEMBL
CHEMBL2093999
ZINC
ZINC000004392967
Wikipedia
Istaroxime

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHeart Failure1
2RecruitingTreatmentShock, Cardiogenic1
2Unknown StatusTreatmentDecompensated Heart Failure1
2WithdrawnTreatmentHeart Failure1
1Unknown StatusTreatmentHealthy Volunteers1
1WithdrawnTreatmentHeart Failure1
0WithdrawnBasic ScienceCongestive Heart Failure (CHF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0174 mg/mLALOGPS
logP2.4ALOGPS
logP2.64ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)8.84ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area81.75 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity99.7 m3·mol-1ChemAxon
Polarizability41.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Details1. Sarcoplasmic/endoplasmic reticulum calcium ATPase 2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
S100 protein binding
Specific Function
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen. Isoform 2 is involved in the regulati...
Gene Name
ATP2A2
Uniprot ID
P16615
Uniprot Name
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2
Molecular Weight
114755.765 Da
References
  1. Mattera GG, Lo Giudice P, Loi FM, Vanoli E, Gagnol JP, Borsini F, Carminati P: Istaroxime: a new luso-inotropic agent for heart failure. Am J Cardiol. 2007 Jan 22;99(2A):33A-40A. Epub 2006 Sep 18. [PubMed:17239702]
Details2. Sodium/potassium-transporting ATPase subunit alpha-1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Mattera GG, Lo Giudice P, Loi FM, Vanoli E, Gagnol JP, Borsini F, Carminati P: Istaroxime: a new luso-inotropic agent for heart failure. Am J Cardiol. 2007 Jan 22;99(2A):33A-40A. Epub 2006 Sep 18. [PubMed:17239702]

Drug created on March 19, 2008 16:14 / Updated on June 12, 2020 16:52